Literature DB >> 19644143

Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.

Nicolas Goardon1, Emmanouil Nikolousis, Alexander Sternberg, Wai-Kit Chu, Charles Craddock, Peter Richardson, Richard Benson, Mark Drayson, Graham Standen, Paresh Vyas, Sylvie Freeman.   

Abstract

Diagnosis of myelodysplastic syndrome can be difficult especially in cases with a low blast count and a normal karyotype. Flow cytometry has been used to distinguish myelodysplastic syndrome from non-clonal cytopenias. No one single simple flow cytometric parameter has been proposed to be diagnostic of myelodysplastic syndrome. We have studied samples from 100 myelodysplastic syndrome patients and as control samples; 70 non-clonal cytopenias, 5 subjects with normal hematology, 31 patients with acute myeloid leukemia and 11 with chronic myelomonocytic leukemia or myeloproliferative disorder. We show that reduced relative mean fluorescence of CD38 below a threshold value on CD34(+) cells diagnosed low-grade myelodysplastic syndrome with 95% sensitivity (95% confidence interval, 87-99%) and 92% specificity (95% confidence interval, 82-97%). This simple flow cytometric test may be of value in the routine clinical diagnosis of myelodysplastic syndrome, especially in cases with a low blast count and normal karyotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644143      PMCID: PMC2719039          DOI: 10.3324/haematol.2008.004085

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  16 in total

Review 1.  Myelodysplasia.

Authors:  M L Heaney; D W Golde
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

2.  Immunophenotypic analysis of myelodysplastic syndromes.

Authors:  M Consuelo Del Cañizo; M Eugenia Fernández; Antonio López; Belén Vidriales; Eva Villarón; José L Arroyo; Francisco Ortuño; Alberto Orfao; Jesus F San Miguel
Journal:  Haematologica       Date:  2003-04       Impact factor: 9.941

3.  Isolation and characterization of human myeloid progenitor populations--TpoR as discriminator between common myeloid and megakaryocyte/erythroid progenitors.

Authors:  Louise Edvardsson; Josefina Dykes; Tor Olofsson
Journal:  Exp Hematol       Date:  2006-05       Impact factor: 3.084

4.  Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.

Authors:  Elisangela Ribeiro; Sergio Matarraz Sudón; María de Santiago; Carmen S P Lima; Konradin Metze; Manuel Giralt; Sara T O Saad; Alberto Orfao de Matos; Irene Lorand-Metze
Journal:  Leuk Res       Date:  2005-07-07       Impact factor: 3.156

5.  Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.

Authors:  M Stetler-Stevenson; D C Arthur; N Jabbour; X Y Xie; J Molldrem; A J Barrett; D Venzon; M E Rick
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.

Authors:  Denise A Wells; Martin Benesch; Michael R Loken; Carlos Vallejo; David Myerson; Wendy M Leisenring; H Joachim Deeg
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

7.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.

Authors:  Alexander Sternberg; Sally Killick; Tim Littlewood; Chris Hatton; Andy Peniket; Thomas Seidl; Shamit Soneji; Joanne Leach; David Bowen; Claire Chapman; Graham Standen; Edwin Massey; Lisa Robinson; Bipin Vadher; Richard Kaczmarski; Riaz Janmohammed; Kim Clipsham; Andrew Carr; Paresh Vyas
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

8.  The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.

Authors:  S Matarraz; A López; S Barrena; C Fernandez; E Jensen; J Flores; P Bárcena; A Rasillo; J M Sayagues; M L Sánchez; P Hernandez-Campo; J M Hernandez Rivas; C Salvador; N Fernandez-Mosteirín; M Giralt; L Perdiguer; A Orfao
Journal:  Leukemia       Date:  2008-03-13       Impact factor: 11.528

9.  Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.

Authors:  Mariela B Monreal; Maria L Pardo; Miguel A Pavlovsky; Isolda Fernandez; Claudia S Corrado; Isabel Giere; Sandra Sapia; Santiago Pavlovsky
Journal:  Cytometry B Clin Cytom       Date:  2006-03       Impact factor: 3.058

10.  Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.

Authors:  M G Della Porta; L Malcovati; R Invernizzi; E Travaglino; C Pascutto; M Maffioli; A Gallì; S Boggi; D Pietra; L Vanelli; C Marseglia; S Levi; P Arosio; M Lazzarino; M Cazzola
Journal:  Leukemia       Date:  2006-04       Impact factor: 11.528

View more
  5 in total

1.  Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

2.  Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes.

Authors:  Huijuan Jiang; Ningbo Cui; Liyan Yang; Chunyan Liu; Lanzhu Yue; Lifang Guo; Huaquan Wang; Zonghong Shao
Journal:  Oncotarget       Date:  2017-10-06

3.  Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.

Authors:  Silvia Maria Meira Magalhães; Lígia Niero-Melo; Maria de Lourdes Lopes Ferrari Chauffaille; Elvira Deolinda Rodrigues Pereira Velloso; Irene Lorand-Metze; Renata Buzzini; Wanderley Marques Bernardo
Journal:  Hematol Transfus Cell Ther       Date:  2018-07-02

4.  Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.

Authors:  Feng Xu; Xiao Li; Chun-Kang Chang; Juan Guo; Ling-Yun Wu; Qi He; Zheng Zhang; Yang Zhu; Shu-Chen Gu; Wen-Hui Shi; Lu-Xi Song; Ji-Ying Su; Li-Yu Zhou; Xi Zhang; Dong Wu
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

5.  Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.

Authors:  Afshin Shameli; Poonam Dharmani-Khan; Joanne Luider; Iwona Auer; Meer-Taher Shabani-Rad
Journal:  Cytometry B Clin Cytom       Date:  2020-12-24       Impact factor: 3.058

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.